## Abstract ## Objective To evaluate the contribution of metabolites (methotrexate [MTX] and folate polyglutamate [PG] levels) and pharmacogenetic biomarkers in the folate pathway to the effects of MTX in patients with rheumatoid arthritis not previously treated with this antifolate. ## Methods
β¦ LIBER β¦
Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis
β Scribed by Michael H. Weisman; Daniel E. Furst; Grace S. Park; Joel M. Kremer; Katie M. Smith; Daniel J. Wallace; Jacques R. Caldwell; Thierry Dervieux
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 89 KB
- Volume
- 54
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Pharmacogenomic and metabolic biomarkers
β
Thierry Dervieux; Neal Greenstein; Joel Kremer
π
Article
π
2006
π
John Wiley and Sons
π
English
β 166 KB
Efficacy and toxicity of methotrexate in
β
Judith A. M. Wessels; Jeska K. de Vries-Bouwstra; Bas T. Heijmans; P. Eline Slag
π
Article
π
2006
π
John Wiley and Sons
π
English
β 97 KB
π 2 views
Polyglutamation of methotrexate with com
β
Thierry Dervieux; Daniel Furst; Diana Orentas Lein; Robert Capps; Katie Smith; M
π
Article
π
2004
π
John Wiley and Sons
π
English
β 197 KB
π 2 views
## Abstract ## Objective Methotrexate (MTX) enters cells through the reduced folate carrier (RFCβ1) and exerts part of its effects through polyglutamation to MTX polyglutamates (MTXPGs) and inhibition of 5βaminoimidazoleβ4βcarboxamide ribonucleotide transformylase (ATIC) and thymidylate synthase (